CANbridge Pharmaceuticals Inc. (01228.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.7x

Market Cap

HKD 870.86M

MomentumView details →

1D Return

−0.52%

YTD Return

−25.00%

RSI (14)

44.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.7x

Market Cap

HKD 870.86M

RSI (14)

44.2

MomentumView details →

1D Return

−0.52%

YTD Return

−25.00%

ProfitabilityView details →

Gross Margin

73.13%

Net Margin

29.65%

EBITDA Margin

−159.36%

ROE (TTM)

−4.34%

ROA (TTM)

8.96%

Asset Turnover

0.30x

GrowthView details →

Revenue YoY

−41.27%

EPS YoY

+104.56%

FCF YoY

+68.80%

Revenue CAGR 3Y

−14.14%

EPS CAGR 3Y

+102.88%

EBITDA YoY

+75.72%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−0.05x

Current Ratio

0.24x

Quick Ratio

0.20x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

49.98M

Net Income (TTM)

14.82M

Op. CF (TTM)

−38.21M

Next earningsApr 1, 2027 →

Latest newsMore news →

Canbridge Pharmaceuticals has initiated the registration process and commercialization preparations for its drug Velafermin β in key North African markets.36d ago

Similar companies

Achieve Life Sciences, Inc.ACHV Silence Therapeutics plcSLN Theravance Biopharma, Inc.TBPH Climb Bio, Inc.CLYM Cybin Inc. Common StockHELP DBV Technologies S.A.DBVT Find similar companies →

Latest newsMore news →

Canbridge Pharmaceuticals has initiated the registration process and commercialization preparations for its drug Velafermin β in key North African markets.36d ago